TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

Oncology Today with Dr Neil Love · Aug 1, 2026 · 54m

Featuring an interview with Dr Ramez Eskander, including the following topics:

Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)

Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)

Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)

Current and investigational targets of ADCs in gynecologic cancers (17:14)

Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role…